KLK3 and cancer: This variation is likely driven by disparities in life expectancy, healthcare access, and the widespread implementation of prostate-specific antigen (PSA) screening, as well as variations in cancer registry reporting practices, all of which contribute to regional differences in prostate cancer incidence and diagnosis.